Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 10/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.52 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3651755 | 1.00 | SMO (0.53) | SMOGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL3696388 | 0.96 | SMO (0.53) | SMOGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL3696386 | 0.96 | SMO (0.53) | SMOGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL10441596 | 0.96 | SMO (0.53) | SMOGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL1102296 | 0.88 | SMO (0.52) | SMOSMARCA2SMARCA4PBRM1 | |
| SCHEMBL2276473 | 0.88 | SMO (0.52) | SMOSMARCA2SMARCA4PBRM1 | |
| SCHEMBL2276478 | 0.88 | SMO (0.52) | SMOSMARCA2SMARCA4PBRM1 | |
| SCHEMBL3652380 | 0.86 | SMO (0.73) | SMOGPR119 | |
| SCHEMBL4162954 | 0.86 | SMO (0.73) | SMOGPR119 | |
| SCHEMBL4158731 | 0.84 | SMO (0.73) | SMOGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188283-B1 | ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING | AMGEN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8222251-B2 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222251-B2 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | DPYD, CYP3A5, PNPO | SMO 2449/4885GPR119 3913/4885SMARCA2 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.